X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.
波士頓，2024 年 4 月 30 日（GLOBE NEWSWIRE）— X4 製藥有限公司（納斯達克股票代碼：XFOR）是一家致力於改善罕見免疫系統疾病患者生活的公司，今天宣佈，它將公佈截至2024年3月31日的第一季度財務業績，並於2024年5月7日星期二提供公司最新情況。
The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13745487. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website.
該公司將在美國東部時間同一天上午 8:30 舉辦電話會議和網絡直播。可以通過從美國撥打1-877-451-6152或在國際上撥打1-201-389-0879來參加電話會議，然後撥打會議ID：13745487。網絡直播可通過X4 Pharmaceuticals網站的投資者關係欄目觀看 www.x4pharma.com。電話會議結束後，將在網站上提供網絡直播重播。
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
關於 X4 製藥
X4通過爲患有罕見免疫系統疾病和重大未滿足需求的患者開發和商業化創新療法，爲患者帶來進步。利用我們在CXCR4 和免疫系統生物學方面的專業知識，我們成功開發了馬沃裏沙福爾，其首個適應症作爲XOLREMDI（馬伏裏沙福）膠囊已獲得美國批准。我們還在評估馬沃裏沙福在其他潛在適應症中的使用。X4 公司總部位於馬薩諸塞州波士頓，我們的卓越研究中心位於奧地利維也納。欲了解更多信息，請訪問我們的網站 www.x4pharma.com。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司聯繫人：
何塞·尤文斯
企業和患者事務主管
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投資者聯繫人：
丹尼爾·費裏
LifeSci Advisors董事總經理
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals
來源：X4 Pharmicals
譯文內容由第三人軟體翻譯。